Hannover Biomedical Research School was founded in 2003. It was supported in the course of the German Excellence Initiative (DFG/BMBF) from 2006 to 2014.
HBRS currently comprises of five international (MD)/PhD programs [“Molecular Medicine”, “Infection Biology”(& DEWIN: Dynamik der Erreger-Wirt Interaktionen), “Regenerative Sciences”, "Auditory Sciences" and "Epidemiology"]. All students who are members of various European Union funded training sites (e.g. Marie Curie ITNs) and who are working on their PhD thesis at MHH research groups are naturally associated to HBRS programs. All PhD programs are in English.
Two structured doctoral program for medical students were also successfully established (StrucMed and KlinStrucMed; for a Dr.med./Dr.med.dent.), as well as two HBRS-associated Master programs “Biomedicine” (start October 2007) and “Biochemistry” (start October 2008).
In 2011, MHH and partner institutes have founded the "Voluntary Research Year" for high school graduates. (more info)
MHH supports young scientists towards an academic career beyond PhD. Therefore, the young faculty program was recently added.
Currently, the various programs of HBRS host ~250 PhD students. In addition, ~50 medical students were accepted for StrucMed, 10 students start the new KlinStrucMed program as well as 60 new Master students (in two programs) will start this year. There are about 50% international and around 5% medical doctors doing their PhD (~50% women).
All PhD students are fully financed, usually by the departments. You will either receive a stipend or are employed with MHH. HBRS is giving six stipends of 18 months to selected students. Please see more here.
Rules and Regulations
You may find details about the organs of HBRS in the HBRS rules (see "HBRS Rules and Regulations").
These are our current PhD rules (please note that in doubt, the German rules and regulations are binding. You find these in the HBRS downloads!)
Application: please find out more here
Contact/ Way to HBRS: please come and see us!
International Advisory Board (IAB)
Joachim R. Kalden (University of Erlangen, Germany),
Steve Keyse (University of Dundee, UK),
Nathalie Cartier (INSERM, Fontanay aux Roses, France),
Hans-Gustaf Ljunggren (Karolinska Institute, Stockholm, Sweden),
Seppo Meri (University of Helsinki, Finland),
Prof. Dr. Marcus Thelen (Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona),
Prof Dr Peter Openshaw: Respiratory Infection, National Heart & Lung Institute (NHLI), Imperial College London, St. Mary's Campus, London